We are a global and independent mid-sized pharmaceutical group governed by a Foundation. Our unique model makes us proud and, more importantly, enables us to fully serve our mission: "committed to therapeutic progress for the benefit of patients."
As a global leader in cardiology, we aim to become a focused and innovative player in oncology by 2030, targeting hard-to-treat cancers and dedicating more than 70% of our R&D budget to this goal.
Who are we? 20,000 passionate individuals from over 50 nationalities, driven by an entrepreneurial spirit. Every day, we move forward with and for patients, with and for our teams, motivated by the desire to care, to dare, to grow, and to commit to being useful to those in need.
Come and experience and contribute to our commitment #MovedByYou.
At the heart of one of the world's top eight innovation clusters, the Servier R&D Institute at Paris-Saclay is where visionary science meets a powerful global ecosystem. By uniting our Group's innovation potential with this prestigious center of excellence, we are not only accelerating the future of therapeutic discovery but also championing the global influence of French research.
Are you a fast-learning scientist passionate about pushing the boundaries of bioanalysis for antisense oligonucleotides (ASOs)? We are seeking a Postdoctoral Scientist to join our team. In this role, you will drive the development of high-sensitivity quantitative and qualitative methods for ASOs by leveraging microflow LC coupled with High-Resolution Mass Spectrometry (HRMS), systematically evaluate innovative sample preparation workflows, and contribute to the scientific community through peer-reviewed publications.
Our standard recruitment journey includes the following steps:
At one stage of the process, we would be delighted to welcome you to our site to meet in person and share the environment where we work every day to transform patients' lives!
Please note that this recruitment process may be adapted based on the specific requirements of the position.
We are committed to equal opportunities and developing talents in all their diversity. We value both experience and the desire to engage daily in contributing to therapeutic progress for the benefit of patients. If this offer resonates with you, seize this opportunity to meet us!
Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle.
As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D.
Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion.
--
To report a suspected adverse event with a Servier drug, please visit servier.com
